Serum sclerostin in acute kidney injury patients; [Esclerostina sérica en pacientes con lesión renal aguda]

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Fayed A.; Abdulazim D.O.; Amin M.; Elhadidy S.; Samir H.H.; Salem M.M.; Abd ElAzim I.M.; El Hawary K.E.S.; Sharaf El Din U.A.

Journal: Nefrologia

Publisher: Elsevier Espana S.L.U

Publication Date: January 2022

Volume / Issue: Volume 42 / Issue 1

Pages: 50–55

ISSN: 20132514

DOI: 10.1016/j.nefro.2021.01.010

Scopus: View on Scopus

PubMed: 34074570

Document Type: Article

Access: All Open Access; Gold Open Access


Authors and Affiliations

Fayed A., Nephrology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt; Abdulazim D.O., Rheumatology and Rehabilitation Department, School of Medicine, Cairo University, Egypt; Amin M., Critical Care Medicine Department, School of Medicine, Cairo University, Egypt; Elhadidy S., Critical Care Medicine Department, School of Medicine, Cairo University, Egypt; Samir H.H., Nephrology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt; Salem M.M., Endocrinology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt; Abd ElAzim I.M., Critical Care Medicine, Theodor Bilharz Research Institute, Cairo, Egypt; El Hawary K.E.S., Radiodiagnosis Department, National Liver Institute-Menofeya University, Egypt; Sharaf El Din U.A., Nephrology Unit, Internal Medicine Department, School of Medicine, Cairo University, Egypt


Abstract

Background: Many of the mineral metabolite abnormalities encountered in chronic kidney disease (CKD) patients were found also associated with acute kidney injury (AKI). In the last decade, sclerostin was found to intimately affect bone mineral metabolism in CKD patients. Nothing is known about sclerostin in AKI. Objective: We looked for serum level of sclerostin in AKI patients in comparison to normal control subjects and if there is an impact on metabolic derangement, endothelial function or clinical outcome. Cases and methods: This is a cross sectional case control observational study of 219 AKI cases (group I) beside 219 age matched normal control subjects (group II). All cases of group I were in the intensive care because of sepsis; 86 had acute on CKD (group Ib), while 133 had de novo AKI (group Ia). All studied subjects underwent estimation of serum sclerostin, parathyroid hormone (PTH), 25 hydroxy vitamin D (25 OH vit D), fibroblast growth factor 23 (FGF23), C-reactive protein (CRP), interleukin 6 (IL6), Homeostatic Model Assessment for Insulin Resistance (Homa IR), beside the routine CBC, kidney and liver function tests, serum calcium, and phosphorus, and flow mediated vasodilation of brachial artery (FMD). Follow-up of group I cases was done till they recovered or passed away. Results: Serum sclerostin, PTH, FGF23, phosphorus, CRP, IL6, HOMA IR, creatinine, urea, uric acid, ALT, AST and white blood cell count (WBC) were significantly higher while serum calcium, 25 OH vit D, hemoglobin, platelet count and FMD were significantly lower in group I compared to group II (P < 0.001 in all). On the other hand, there was no significant difference in serum sclerostin, PTH, FGfF23, 25 OH vit D, CRP, IL6, Homa IR and FMD between group Ia and Ib. Survivors were younger in age (median 55.5 vs. 60 years, P < 0.04), had lower AST (30.5 vs. 58 units, P < 0.001), had higher platelet count (206 vs 162 × 109/L, P < 0.001), otherwise, there was no significant difference in any of the other parameters between survivors and patients that were lost. Serum sclerostin had strong correlation with FGF23 in group I (r = 0.99, P < 0.001) and group II (r = 1, P < 0.001). Homa IR had positive correlation with serum sclerostin (r = 0.148, P = 0.014) and serum FGF23 (r = 0.142, P = 0.018) in group I. Conclusion: Sclerostin is intimately related to FGF23. Sclerostin level increases in AKI patients. Both sclerostin and FGF23 might increase insulin resistance but have no impact on FMD. Neither sclerostin nor FGF23 interfere with AKI outcome. © 2021 Sociedad Española de Nefrología


Keywords

AKI; FGF23; Insulin resistance; Sclerostin; Sepsis; Acute Kidney Injury; Biomarkers; C-Reactive Protein; Calcium; Creatinine; Cross-Sectional Studies; Fibroblast Growth Factors; Humans; Interleukin-6; Minerals; Parathyroid Hormone; Phosphorus; Renal Insufficiency, Chronic; Urea; Uric Acid; Vitamin D; 25 hydroxyvitamin D; alanine aminotransferase; aspartate aminotransferase; C reactive protein; fibroblast growth factor 23; interleukin 6; biological marker; fibroblast growth factor; mineral; acute kidney failure; adult; alanine aminotransferase level; Article; aspartate aminotransferase blood level; blood cell count; brachial artery; calcium blood level; case control study; cell function; controlled study; creatinine blood level; cross-sectional study; endothelium; follow up; homeostasis model assessment; human; human cell; intensive care; kidney function test; leukocyte count; liver function test; major clinical study; middle aged; mortality rate; observational study; parathyroid hormone blood level; pathogenesis; phosphate blood level; platelet count; protein blood level; urea blood level; uric acid blood level; vitamin blood level; chronic kidney failure; metabolism


Citation Information

Scopus Citations: 2


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer